Olaf van Tellingen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Feces

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Pluim Dick; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.
Borovski Tijana; Verhoeff Joost J C; ten Cate Rosemarie; Cameron Kate; de Vries Nienke A; van Tellingen Olaf; Richel Dirk J; van Furth Wouter R; Medema Jan Paul; Sprick Martin R
Tumor microvasculature supports proliferation and expansion of glioma-propagating cells.
Abraham Jame; Edgerly Maureen; Wilson Richard; Chen Clara; Rutt Ann; Bakke Susan; Robey Rob; Dwyer Andrew; Goldspiel Barry; Balis Frank; Van Tellingen Olaf; Bates Susan E; Fojo Tito
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Olaf van Tellingen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Pluim Dick; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3549-55.
2009: Borovski Tijana; Verhoeff Joost J C; ten Cate Rosemarie; Cameron Kate; de Vries Nienke A; van Tellingen Olaf; Richel Dirk J; van Furth Wouter R; Medema Jan Paul; Sprick Martin R
Tumor microvasculature supports proliferation and expansion of glioma-propagating cells.
International journal of cancer. Journal international du cancer 2009;125(5):1222-30.
2009: Abraham Jame; Edgerly Maureen; Wilson Richard; Chen Clara; Rutt Ann; Bakke Susan; Robey Rob; Dwyer Andrew; Goldspiel Barry; Balis Frank; Van Tellingen Olaf; Bates Susan E; Fojo Tito
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3574-82.
2009: Vlaming Maria L H; Pala Zeliha; van Esch Anita; Wagenaar Els; de Waart Dirk R; van de Wetering Koen; van der Kruijssen Cornelia M M; Oude Elferink Ronald P J; van Tellingen Olaf; Schinkel Alfred H
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3084-93.
2009: Beumer Jan Handrick; Lopez-Lazaro L; Schellens Jan H M; Beijnen Jos H; van Tellingen Olaf
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
Current clinical pharmacology 2009;4(1):38-42.
2009: Niers Tatjana M H; Brüggemann Lois W; Klerk Clara P W; Muller Femke J M; Buckle Tessa; Reitsma Pieter H; Richel Dick J; Spek C Arnold; Van Tellingen Olaf; Van Noorden Cornelis J F
Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung.
Clinical & experimental metastasis 2009;26(3):171-8.
2008: Marchetti Serena; de Vries Nienke A; Buckle Tessa; Bolijn Maria J; van Eijndhoven Maria A J; Beijnen Jos H; Mazzanti Roberto; van Tellingen Olaf; Schellens Jan H M
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Molecular cancer therapeutics 2008;7(8):2280-7.
2008: Veltkamp Stephan A; Pluim Dick; van Tellingen Olaf; Beijnen Jos H; Schellens Jan H M
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(8):1606-15.
2008: Gambarota G; Leenders W; Maass C; Wesseling P; van der Kogel B; van Tellingen O; Heerschap A
Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI.
British journal of cancer 2008;98(11):1784-9.
2008: Claes An; Gambarota Giulio; Hamans Bob; van Tellingen Olaf; Wesseling Pieter; Maass Cathy; Heerschap Arend; Leenders William
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
International journal of cancer. Journal international du cancer 2008;122(9):1981-6.
2008: Seigers Riejanne; Schagen Sanne B; Beerling Wieteke; Boogerd Willem; van Tellingen Olaf; van Dam Frits S A M; Koolhaas Jaap M; Buwalda Bauke
Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat.
Behavioural brain research 2008;186(2):168-75.
2007: Marchetti Serena; Oostendorp Roos L; Pluim Dick; van Eijndhoven Monique; van Tellingen Olaf; Schinkel Alfred H; Versace Richard; Beijnen Jos H; Mazzanti Roberto; Schellens Jan H
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Molecular cancer therapeutics 2007;6(12 Pt 1):3307-13.
2007: van Herwaarden Antonius E; Wagenaar Els; van der Kruijssen Cornelia M M; van Waterschoot Robert A B; Smit Johan W; Song Ji-Ying; van der Valk Martin A; van Tellingen Olaf; van der Hoorn José W A; Rosing Hilde; Beijnen Jos H; Schinkel Alfred H
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
The Journal of clinical investigation 2007;117(11):3583-92.
2007: de Vries Nienke A; Zhao Jin; Kroon Emily; Buckle Tessa; Beijnen Jos H; van Tellingen Olaf
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6440-9.
2007: de Vries Nienke A; Ouwehand Mariët; Buckle Tessa; Beijnen Jos H; van Tellingen Olaf
Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.
Biomedical chromatography : BMC 2007;21(11):1191-200.
2007: Bruggeman Sophia W M; Hulsman Danielle; Tanger Ellen; Buckle Tessa; Blom Marleen; Zevenhoven John; van Tellingen Olaf; van Lohuizen Maarten
Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.
Cancer cell 2007;12(4):328-41.
2007: Klerk Clara P W; Overmeer Renée M; Niers Tatjana M H; Versteeg Henri H; Richel Dick J; Buckle Tessa; Van Noorden Cornelis J F; van Tellingen Olaf
Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals.
BioTechniques 2007;43(1 Suppl):7-13, 30.
2007: Rottenberg Sven; Nygren Anders O H; Pajic Marina; van Leeuwen Fijs W B; van der Heijden Ingrid; van de Wetering Koen; Liu Xiaoling; de Visser Karin E; Gilhuijs Kenneth G; van Tellingen Olaf; Schouten Jan P; Jonkers Jos; Borst Piet
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(29):12117-22.
2007: Beumer Jan-Hendrik; Buckle Tessa; Ouwehand Mariet; Franke Niels E F; Lopez-Lazaro Luis; Schellens Jan H M; Beijnen Jos H; van Tellingen Olaf
Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.
Investigational new drugs 2007;25(1):1-7.
2006: Kemper E M; Leenders W; Küsters B; Lyons S; Buckle T; Heerschap A; Boogerd W; Beijnen J H; van Tellingen O
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
European journal of cancer (Oxford, England : 1990) 2006;42(18):3294-303.
2006: Lagas Jurjen S; Vlaming Maria L; van Tellingen Olaf; Wagenaar Els; Jansen Robert S; Rosing Hilde; Beijnen Jos H; Schinkel Alfred H
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6125-32.
2006: de Vries Nienke A; Beijnen Jos H; Boogerd Willem; van Tellingen Olaf
Blood-brain barrier and chemotherapeutic treatment of brain tumors.
Expert review of neurotherapeutics 2006;6(8):1199-209.
2006: Vlaming M L H; Mohrmann K; Wagenaar E; de Waart D R; Elferink R P J Oude; Lagas J S; van Tellingen O; Vainchtein L D; Rosing H; Beijnen J H; Schellens J H M; Schinkel A H
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
The Journal of pharmacology and experimental therapeutics 2006;318(1):319-27.
2006: Press Rogier R; Buckle Tessa; Beijnen Jos H; van Tellingen Olaf
The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Cancer chemotherapy and pharmacology 2006;57(6):819-25.
2005: Bardelmeijer Heleen A; Roelofs Arjan B G H; Hillebrand Michel J X; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Metabolism of docetaxel in mice.
Cancer chemotherapy and pharmacology 2005;56(3):299-306.
2005: Huisman Maarten T; Chhatta Aniska A; van Tellingen Olaf; Beijnen Jos H; Schinkel Alfred H
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
International journal of cancer. Journal international du cancer 2005;116(5):824-9.
2005: Brouwers E E M; Tibben M M; Joerger M; van Tellingen O; Rosing H; Schellens J H M; Beijnen J H
Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2005;382(7):1484-90.
2005: Breedveld Pauline; Pluim Dick; Cipriani Greta; Wielinga Peter; van Tellingen Olaf; Schinkel Alfred H; Schellens Jan H M
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Cancer research 2005;65(7):2577-82.
2005: van Tellingen Olaf; Bardelmeijer Heleen A; Buckle Tessa; Ouwehand Mariet; Beijnen Jos H; Schellens Jan H M
Cannulation of the jugular vein in mice.
Laboratory animals 2005;39(1):130.
2004: Stokvis E; Ouwehand M; Nan L G A H; Kemper E M; van Tellingen O; Rosing H; Beijnen J H
A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(12):1506-12.
2004: Breedveld Pauline; Zelcer Noam; Pluim Dick; Sönmezer Ozgür; Tibben Matthijs M; Beijnen Jos H; Schinkel Alfred H; van Tellingen Olaf; Borst Piet; Schellens Jan H M
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Cancer research 2004;64(16):5804-11.
2004: Kemper E Marleen; Boogerd Willem; Thuis Ingrid; Beijnen Jos H; van Tellingen Olaf
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
Cancer treatment reviews 2004;30(5):415-23.
2004: Bardelmeijer Heleen A; Ouwehand Mariët; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Investigational new drugs 2004;22(3):219-29.
2004: Kemper E M; Verheij M; Boogerd W; Beijnen J H; van Tellingen O
Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1269-74.
2004: Kemper E Marleen; Cleypool Cindy; Boogerd Willem; Beijnen Jos H; van Tellingen Olaf
The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Cancer chemotherapy and pharmacology 2004;53(2):173-8.
2004: van den Bongard H J G Desirée; Kemper E Marleen; van Tellingen Olaf; Rosing Hilde; Mathôt Ron A A; Schellens Jan H M; Beijnen Jos H
Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.
Analytical biochemistry 2004;324(1):11-5.
2003: Kemper E M; Ouwehand M; Beijnen J H; van Tellingen O
Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;798(1):63-8.
2003: van Tellingen O; Buckle T; Jonker J W; van der Valk M A; Beijnen J H
P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.
British journal of cancer 2003;89(9):1776-82.
2003: Bardelmeijer H A; Buckle T; Ouwehand M; Beijnen J H; Schellens J H M; van Tellingen O
Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.
Laboratory animals 2003;37(3):181-7.
2003: Kemper E Marleen; van Zandbergen A Erik; Cleypool Cindy; Mos Henk A; Boogerd Willem; Beijnen Jos H; van Tellingen Olaf
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2849-55.
2003: Allen John D; Van Dort Sonja C; Buitelaar Marije; van Tellingen Olaf; Schinkel Alfred H
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Cancer research 2003;63(6):1339-44.
2003: Bardelmeijer Heleen A; Oomen Ingrid A M; Hillebrand Michel J X; Beijnen Jos H; Schellens Jan H M; van Tellingen Olaf
Metabolism of paclitaxel in mice.
Anti-cancer drugs 2003;14(3):203-9.
2003: van Ruth S; van Tellingen O; Korse C M; Verwaal V J; Zoetmulder F A N
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.
Anti-cancer drugs 2003;14(1):57-65.
2002: Bardelmeijer Heleen A; Ouwehand Mariët; Buckle Tessa; Huisman Maarten T; Schellens Jan H M; Beijnen Jos H; van Tellingen Olaf
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Cancer research 2002;62(21):6158-64.
2002: van den Bongard H J G D; Mathôt R A A; van Tellingen O; Schellens J H M; Beijnen J H
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Cancer chemotherapy and pharmacology 2002;50(1):16-24.
2002: Allen John D; van Loevezijn Arnold; Lakhai Jeany M; van der Valk Martin; van Tellingen Olaf; Reid Glen; Schellens Jan H M; Koomen Gerrit-Jan; Schinkel Alfred H
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Molecular cancer therapeutics 2002;1(6):417-25.
2002: Bardelmeijer Heleen A; Ouwehand Mariët; Malingré Mirte M; Schellens Jan H M; Beijnen Jos H; van Tellingen Olaf
Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Cancer chemotherapy and pharmacology 2002;49(2):119-25.
2001: Malingré M M; Schellens J H; Van Tellingen O; Ouwehand M; Bardelmeijer H A; Rosing H; Koopman F J; Schot M E; Ten Bokkel Huinink W W; Beijnen J H
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
British journal of cancer 2001;85(10):1472-7.
2001: Bardelmeijer H A; Ouwehand M; Beijnen J H; Schellens J H; van Tellingen O
Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):201-6.
2001: Kemper E M; Jansen B; Brouwer K R; Schellens J H; Beijnen J H; van Tellingen O
Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(1):135-43.
2001: Malingré M M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; Ten Bokkel Huinink W W; Swart M; Lieverst J; Schellens J H
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Cancer chemotherapy and pharmacology 2001;47(4):347-54.
2001: Malingré M M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; ten Bokkel Huinink W W; Swart M; Lieverst J; Schellens J H
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Anti-cancer drugs 2001;12(4):351-8.
2001: Crul M; van den Bongard H J; Tibben M M; van Tellingen O; Sava G; Schellens J H; Beijnen J H
Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2001;369(5):442-5.
2000: Schellens J H; Malingré M M; Kruijtzer C M; Bardelmeijer H A; van Tellingen O; Schinkel A H; Beijnen J H
Modulation of oral bioavailability of anticancer drugs: from mouse to man.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;12(2):103-10.
2000: Malingré M M; Schellens J H; van Tellingen O; Rosing H; Koopman F J; Duchin K; Huinink W W; Swart M; Beijnen J H
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
Anti-cancer drugs 2000;11(10):813-20.
2000: Bardelmeijer H A; Beijnen J H; Brouwer K R; Rosing H; Nooijen W J; Schellens J H; van Tellingen O
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4416-21.
2000: Meerum Terwogt J; van Tellingen O; Nannan Panday V R; Huizing M T; Schellens J H; ten Bokkel Huinink W W; Boschma M U; Giaccone G; Veenhof C H; Beijnen J H
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Anti-cancer drugs 2000;11(9):687-94.
2000: Bardelmeijer H A; van Tellingen O; Schellens J H; Beijnen J H
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Investigational new drugs 2000;18(3):231-41.
2000: Malingré M M; Terwogt J M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; Huinink W W; Swart M; Lieverst J; Schellens J H
Phase I and pharmacokinetic study of oral paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2468-75.
2000: van Asperen J; van Tellingen O; Beijnen J H
The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(3):264-7.
1999: Meerum Terwogt J M; Malingré M M; Beijnen J H; ten Bokkel Huinink W W; Rosing H; Koopman F J; van Tellingen O; Swart M; Schellens J H
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3379-84.
1999: Smit J W; Huisman M T; van Tellingen O; Wiltshire H R; Schinkel A H
Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
The Journal of clinical investigation 1999;104(10):1441-7.
1999: van Tellingen O; Beijnen J H; Verweij J; Scherrenburg E J; Nooijen W J; Sparreboom A
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2918-24.
1999: van Tellingen O; Huizing M T; Panday V R; Schellens J H; Nooijen W J; Beijnen J H
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
British journal of cancer 1999;81(2):330-5.
1999: Sparidans R W; Kettenes-van den Bosch J J; van Tellingen O; Nuyen B; Henrar R E; Jimeno J M; Faircloth G; Floriano P; Rinehart K L; Beijnen J H
Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole.
Journal of chromatography. B, Biomedical sciences and applications 1999;729(1-2):43-53.
1999: van Asperen J; van Tellingen O; Schinkel A H; Beijnen J H
Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.
The Journal of pharmacology and experimental therapeutics 1999;289(1):329-33.
1999: Awada A; Punt C J; Piccart M J; Van Tellingen O; Van Manen L; Kerger J; Groot Y; Wanders J; Verweij J; Wagener D J
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule.
British journal of cancer 1999;79(9-10):1454-61.
1999: van Asperen J; van Tellingen O; Tijssen F; Schinkel A H; Beijnen J H
Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
British journal of cancer 1999;79(1):108-13.
1999: van Gijn R; ten Bokkel Huinink W W; Rodenhuis S; Vermorken J B; van Tellingen O; Rosing H; van Warmerdam L J; Beijnen J H
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs 1999;10(1):17-23.
1999: van Gijn R; van Tellingen O; Haverkate E; Kettenes-van den Bosch J J; Bult A; Beijnen J H
Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.
Investigational new drugs 1999;17(1):29-41.
1998: van Tellingen O; Kemper M; Tijssen F; van Asperen J; Nooijen W J; Beijnen J H
High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):251-7.
1998: van Asperen J; van Tellingen O; van der Valk M A; Rozenhart M; Beijnen J H
Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2293-7.
1998: Panday V R; ten Bokkel Huinink W W; Rosing H; Koopman F J; Hillebrand M J; Dubbelman R C; van Tellingen O; Schellens J H; Beijnen J H
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Anti-cancer drugs 1998;9(8):665-73.
1998: van Asperen J; van Tellingen O; Beijnen J H
Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):129-43.
1998: Van Asperen J; Van Tellingen O; Beijnen J H
The pharmacological role of P-glycoprotein in the intestinal epithelium.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;37(6):429-35.
1998: van Tellingen O; Nooijen W J; Schaaf L J; van der Valk M; van Asperen J; Henrar R E; Beijnen J H
Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
Cancer research 1998;58(11):2410-6.
1998: van de Vaart P J; van der Vange N; Zoetmulder F A; van Goethem A R; van Tellingen O; ten Bokkel Huinink W W; Beijnen J H; Bartelink H; Begg A C
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1998;34(1):148-54.
1998: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Preclinical pharmacokinetics of paclitaxel and docetaxel.
Anti-cancer drugs 1998;9(1):1-17.
1998: van Tellingen O; Punt C J; Awada A; Wagener D J; Piccart M J; Groot Y; Schaaf L J; Henrar R E; Nooijen W J; Beijnen J H
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.
Cancer chemotherapy and pharmacology 1998;41(5):377-84.
1997: van Asperen J; Mayer U; van Tellingen O; Beijnen J H
The functional role of P-glycoprotein in the blood-brain barrier.
Journal of pharmaceutical sciences 1997;86(8):881-4.
1997: Schinkel A H; Mayer U; Wagenaar E; Mol C A; van Deemter L; Smit J J; van der Valk M A; Voordouw A C; Spits H; van Tellingen O; Zijlmans J M; Fibbe W E; Borst P
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(8):4028-33.
1997: Sparreboom A; van Asperen J; Mayer U; Schinkel A H; Smit J W; Meijer D K; Borst P; Nooijen W J; Beijnen J H; van Tellingen O
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(5):2031-5.
1997: van Asperen J; van Tellingen O; Sparreboom A; Schinkel A H; Borst P; Nooijen W J; Beijnen J H
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
British journal of cancer 1997;76(9):1181-3.
1997: van Tellingen O; Boogerd W; Nooijen W J; Beijnen J H
The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.
Cancer chemotherapy and pharmacology 1997;40(4):330-4.
1996: Wolff I; Bench K; Beijnen J H; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1717-23.
1996: de Wit R; Beijnen J H; van Tellingen O; Schellens J H; de Boer-Dennert M; Verweij J
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
British journal of cancer 1996;74(2):323-6.
1996: van Asperen J; Schinkel A H; Beijnen J H; Nooijen W J; Borst P; van Tellingen O
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
Journal of the National Cancer Institute 1996;88(14):994-9.
1996: Sparreboom A; van Tellingen O; Huizing M T; Nooijen W J; Beijnen J H
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;681(2):355-62.
1996: Sparreboom A; Van Tellingen O; Scherrenburg E J; Boesen J J; Huizing M T; Nooijen W J; Versluis C; Beijnen J H
Isolation, purification and biological activity of major docetaxel metabolites from human feces.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(6):655-8.
1996: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Cancer research 1996;56(9):2112-5.
1996: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Tissue distribution, metabolism and excretion of paclitaxel in mice.
Anti-cancer drugs 1996;7(1):78-86.
1996: van Tellingen O; Kuck M T; Vlasveld L T; Rodenhuis S; Nooijen W J; Beijnen J H
Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.
Cancer chemotherapy and pharmacology 1996;38(4):387-90.
1995: van Gijn R; Havik E; Boven E; Vermorken J B; ten Bokkel Huinink W W; van Tellingen O; Beijnen J H
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Journal of pharmaceutical and biomedical analysis 1995;14(1-2):165-74.
1995: Huizing M T; Sparreboom A; Rosing H; van Tellingen O; Pinedo H M; Beijnen J H
Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;674(2):261-8.
1995: van Warmerdam L J; van Tellingen O; ten Bokkel Huinink W W; Rodenhuis S; Maes R A; Bijnen J H
Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?
Therapeutic drug monitoring 1995;17(5):465-70.
1995: Zaman G J; Lankelma J; van Tellingen O; Beijnen J; Dekker H; Paulusma C; Oude Elferink R P; Baas F; Borst P
Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(17):7690-4.
1995: van Gijn R; van Tellingen O; de Clippeleir J J; Hillebrand M J; Boven E; Vermorken J B; ten Bokkel Huinink W W; Schwertz S; Graf P; Beijnen J H
Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;667(2):269-76.
1995: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;664(2):383-91.
1995: Sparreboom A; Huizing M T; Boesen J J; Nooijen W J; van Tellingen O; Beijnen J H
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.
Cancer chemotherapy and pharmacology 1995;36(4):299-304.
1994: van Tellingen O
Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids.
Pharmacy world & science : PWS 1994;16(3):164-6.
1994: Schinkel A H; Smit J J; van Tellingen O; Beijnen J H; Wagenaar E; van Deemter L; Mol C A; van der Valk M A; Robanus-Maandag E C; te Riele H P
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.
Cell 1994;77(4):491-502.
1994: van Tellingen O; Pels E M; Henrar R E; Schaaf L J; Padbury G E; Beijnen J H; Nooijen W J
Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.
Journal of chromatography 1994;652(1):51-8.
1994: van Tellingen O; Sonneveldt A L; Beijnen J H; Nooijen W J; Kettenes-van den Bosch J J; Versluis C; Bult A
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.
Cancer chemotherapy and pharmacology 1994;33(5):425-34.
1994: van Warmerdam L J; Rodenhuis S; van Tellingen O; Maes R A; Beijnen J H
Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.
Cancer chemotherapy and pharmacology 1994;35(2):179-81.
1994: Sips J H; van Tellingen O; Nooijen W J; Rodenhuis S; Ten Bokkel Huinink W J; Beijnen J H
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
Cancer chemotherapy and pharmacology 1994;35(2):144-8.
1993: van Gijn R; De Graaff-Teulen M J; van Tellingen O; Beijnen J H
Chemical stability of the new antitumour agent intoplicine in infusion fluids.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1353-6.
1993: van Gijn R; Kuijs S; Rosing H; Dubbelman A C; van Tellingen O; ten Bokkel Huinink W W; Pinedo H M; Beijnen J H
Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1345-8.
1993: van Tellingen O; Beijnen J H; Nooijen W J; Bult A
Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
Cancer research 1993;53(9):2061-5.
1993: van Gijn R; Rosing H; ten Bokkel Huinink W W; van Tellingen O; Vermorken J B; Liefting A J; Bruno R; Pinedo H M; Beijnen J H
Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1993;614(2):299-306.
1993: van Tellingen O; Kuijpers A V; Beijnen J H; Nooijen W J; Bult A
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.
Investigational new drugs 1993;11(2-3):141-50.
1993: van Tellingen O; Beijnen J H; Nooijen W J; Bult A
Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.
Cancer chemotherapy and pharmacology 1993;32(4):286-92.
1992: Burger D M; Rosing H; van Gijn R; Meenhorst P L; van Tellingen O; Beijnen J H
Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography 1992;584(2):239-47.
1992: van Tellingen O; Sips J H; Beijnen J H; Bult A; Nooijen W J
Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review).
Anticancer research 1992;12(5):1699-715.
1992: van Tellingen O; Sips J H; Beijnen J H; Schornagel J H; Nooyen W J
Bioanalysis of the investigational anti-tumour drug 5,10-dideaza-5,6,7,8-tetrahydrofolic acid by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography 1992;576(1):158-62.
1992: van Tellingen O; Beijnen J H; Baurain R; ten Bokkel Huinink W W; van der Woude H R; Nooyen W J
Biodetermination of N-(deacetyl-O-4-vinblastoyl-23)-L-tryptophan, a metabolite of vintriptol, by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;574(2):293-8.
1992: van Tellingen O; Kuijpers A; Beijnen J H; Baselier M R; Burghouts J T; Nooyen W J
Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;573(2):328-32.
1991: van Tellingen O; Beijnen J H; Baurain R; ten Bokkel Huinink W W; van der Woude H R; Nooyen W J
High-performance liquid chromatographic determination of vinblastine, 4-O-deacetylvinblastine and the potential metabolite 4-O-deacetylvinblastine-3-oic acid in biological fluids.
Journal of chromatography 1991;553(1-2):47-53.
1991: Deurloo M J; Kop W; van Tellingen O; Bartelink H; Begg A C
Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution.
Cancer chemotherapy and pharmacology 1991;27(5):347-53.
1991: Terheggen P M; Floot B G; Lempers E L; van Tellingen O; Begg A C; den Engelse L
Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.
Cancer chemotherapy and pharmacology 1991;28(3):185-91.
1991: Oosterkamp H M; Vlasveld L T; Wanders J; Beijnen J H; van Tellingen O; Dubbelman A C; Simonetti G P; Franklin H R; Vermorken J B; Ten Bokkel Huinink W W
Phase I study of vintriptol, a tryptophan ester of vinblastine.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1222-6.
1991: Van Tellingen O; Beijnen J H; Nooyen W J
Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature.
Journal of pharmaceutical and biomedical analysis 1991;9(10-12):1077-82.
1990: van Tellingen O; van der Woude H R; Beijnen J H; Rao K S; ten Bokkel Huinink W W; Nooyen W J
High-performance liquid chromatographic bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug vintriptol.
Journal of chromatography 1990;529(2):329-38.
1990: van Tellingen O; Beijnen J H; van der Woude H R; Bruning P F; Nooyen W J
High-performance liquid chromatographic method for the analysis of 10-ethyl-10-deaza-aminopterin and metabolites in plasma.
Journal of chromatography 1990;529(1):135-43.
1990: van Tellingen O; Beijnen J H; van der Woude H R; Baurain R; ten Bokkel Huinink W W; Nooyen W J
Bio-analysis of N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate, methane sulphonate (VileE) by high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):1029-31.
1989: van Tellingen O; van der Woude H R; Beijnen J H; van Beers C J; Nooyen W J
Stable and sensitive method for the simultaneous determination of N5-methyltetrahydrofolate, leucovorin, methotrexate and 7-hydroxymethotrexate in biological fluids.
Journal of chromatography 1989;488(2):379-88.
1987: van Tellingen O; Bonfrer J M; Nooyen W J; Bruning P F
Improved method for the quantification of aminoglutethimide in urine samples.
Clinica chimica acta; international journal of clinical chemistry 1987;169(1):99-108.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Olaf van Tellingen

Research Profile (preview)

Living Beings

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Olaf van Tellingen (preview)

All Publications